Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1349-1360

  Shiozaki, Yasuyuki ^a   Kitajima, Takashi ^c   Mazaki, Tetsuro ^a   Yoshida, Aki ^a   Tanaka, Masato ^a   Umezawa, Akihiro ^d   Nakamura, Mariko ^e   Yoshida, Yasuhiro ^b   Ito, Yoshihiro ^c   Ozaki, Toshifumi ^a   Matsukawa, Akihiro ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c RIKEN   (Japan)

^d NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^e KIBI INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

BMP4; Bone repair; Bone tissue engineering; Osteogenesis

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; COLLAGEN BINDING DOMAIN BONE MORPHOGENETIC PROTEIN 4; COLLAGEN GEL; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEVELOPMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN STABILITY; SKULL DEFECT;

BMP4; BONE REPAIR; BONE TISSUE ENGINEERING; OSTEOGENESIS;

ANIMALS; BONE MORPHOGENETIC PROTEIN 4; COLLAGEN; DRUG CARRIERS; FEMALE; FIBRONECTINS; HISTOCYTOCHEMISTRY; HUMANS; MICE; NANOPARTICLES; OSTEOGENESIS; RABBITS; RECOMBINANT FUSION PROTEINS; SKULL; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

MUS;

EID: 84876215130     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S44124     Document Type: Article

References (32)

1. Cierny G 3rd, Zorn KE. Segmental tibial defects. Comparing conventional and Ilizarov methodologies. Clin Orthop Relat Res. 1994; 301:118-123.
2. Myeroff C, Archdeacon M. Autogenous bone graft: donor sites and techniques. J Bone Joint Surg Am. 2011;93(23):2227-2236.
3. Linkhart TA, Mohan S, Baylink DJ. Growth factors for bone growth and repair: IGF, TGF beta, and BMP. Bone. 1996;19(Suppl 1):1S-2S.
4. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22(4):233-241.
5. Marsell R, Einhorn TA. The role of endogenous bone morphogenetic proteins in normal skeletal repair. Injury. 2009;40 Suppl 3:S4-S7.
6. McKay WF, Peckham SM, Badura JM. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft). Int Orthop. 2007;31(6):729-734.
7. White AP, Vaccaro AR, Hall JA, Whang PG, Friel BC, McKee MD. Clinical applications of BMP-7/OP-1in fractures, nonunions, and spinal fusion. Int Orthop. 2007;31(6):735-741.
8. Anderson CL, Whitaker MC. Heterotopic ossification associated with recombinant human bone morphogenetic protein-2 (infuse) in posterolateral lumbar spine fusion: a case report. Spine (Phila Pa 1976). 2012;37(8):E502-E506.
9. Joseph V, Rampersaud YR. Heterotopic bone formation with the use of rhBMP2in posterior minimal access interbody fusion: a CT analysis. Spine (Phila Pa 1976). 2007;32(25):2885-2890.
10. Kim PD, Ludwig S, Poelstra K, Duggan B, Scalea T, Gelb D. Ectopic bone formation in the pelvis after combined anterior and posterior fusion of the spine with osteogenic protein-1 use: a case report. J Spinal Disord Tech. 2010;23(3):215-220.
11. Pang EK, Im SU, Kim CS, et al. Effect of recombinant human bone morphogenetic protein-4 dose on bone formation in a rat calvarial defect model. J Periodontol. 2004;75(10):1364-1370.
12. Leong LM, Brickell PM. Bone morphogenic protein-4. Int J Biochem Cell Biol. 1996;28(12):1293-1296.
13. Rundle CH, Miyakoshi N, Kasukawa Y, et al. In vivo bone formation in fracture repair induced by direct retroviral-based gene therapy with bone morphogenetic protein-4. Bone. 2003;32(6):591-601.
14. Lópiz-Morales Y, Abarrategi A, Ramos V, et al. In vivo comparison of the effects of rhBMP-2 and rhBMP-4in osteochondral tissue regeneration. Eur Cell Mater. 2010;20:367-378.
15. Lu H, Kawazoe N, Kitajima T, et al. Spatial immobilization of bone morphogenetic protein-4in a collagen-PLGA hybrid scaffold for enhanced osteoinductivity. Biomaterials. 2012;33(26):6140-6146.
16. Price TM, Rudee ML, Pierschbacher M, Ruoslahti E. Structure of fibronectin and its fragments in electron microscopy. Eur J Biochem. 1982;129(2):359-363.
17. Ishikawa T, Terai H, Kitajima T. Production of a biologically active epidermal growth factor fusion protein with high collagen affinity. J Biochem. 2001;129(4):627-633.
18. Kawamoto T, Shimizu M. A method for preparing 2-to 50-micron-thick fresh-frozen sections of large samples and undecalcified hard tissues. Histochem Cell Biol. 2000;113(5):331-339.
19. Aalami OO, Nacamuli RP, Lenton KA, et al. Applications of a mouse model of calvarial healing: differences in regenerative abilities of juveniles and adults. Plast Reconstr Surg. 2004;114(3):713-720.
20. Robey PG, Fedarko NS, Hefferan TE, et al. Structure and molecular regulation of bone matrix proteins. J Bone Miner Res. 1993;8 Suppl 2: S483-S487.
21. Kitajima T, Ito Y. Artificial binding growth factors. In: Khang G, editor. Handbook of Intelligent Scaffolds for Tissue Engineering and Regenerative Medicine. Singapore: Pan Stanford Publishing; 2012:337-353.
22. Chen B, Lin H, Zhao Y, et al. Activation of demineralized bone matrix by genetically engineered human bone morphogenetic protein-2 with a collagen binding domain derived from von Willebrand factor propolypeptide. J Biomed Mater Res A. 2007;80(2):428-434.
23. Zhao Y, Chen B, Lin H, et al. The bone-derived collagen containing mineralized matrix for the loading of collagen-binding bone morphogenetic protein-2. J Biomed Mater Res A. 2009;88(3):725-734.
24. Chen B, Lin H, Wang J, et al. Homogeneous osteogenesis and bone regeneration by demineralized bone matrix loading with collagen-targeting bone morphogenetic protein-2. Biomaterials. 2007;28(6):1027-1035.
25. Anderson HC, Sipe JB, Hessle L, et al. Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice. Am J Pathol. 2004;164(3):841-847.
26. Bianco P, Riminucci M, Bonucci E, Termine JD, Robey PG. Bone sialoprotein (BSP) secretion and osteoblast differentiation: relationship to bromodeoxyuridine incorporation, alkaline phosphatase, and matrix deposition. J Histochem Cytochem. 1993;41(2):183-191.
27. Galli M, Caniggia M. Osteocalcin. Minerva Med. 1984;75(42):2489-2501. Italian.
28. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002;108(1):17-29.
29. Nishio Y, Dong Y, Paris M, O'Keefe RJ, Schwarz EM, Drissi H. Runx2-mediated regulation of the zinc finger Osterix/Sp7gene. Gene. 2006;372:62-70.
30. Moursi AM, Damsky CH, Lull J, et al. Fibronectin regulates calvarial osteoblast differentiation. J Cell Sci. 1996;109(Pt 6):1369-1380.
31. Moursi AM, Globus RK, Damsky CH. Interactions between integrin receptors and fibronectin are required for calvarial osteoblast differentiation in vitro. J Cell Sci. 1997;110(Pt 18):2187-2196.
32. Mathews S, Bhonde R, Gupta PK, Totey S. Extracellular matrix protein mediated regulation of the osteoblast differentiation of bone marrow derived human mesenchymal stem cells. Differentiation. 2012;84(2):185-192.